Skip to main content
. 2018 Jan 26;97(4):e9757. doi: 10.1097/MD.0000000000009757

Figure 1.

Figure 1

Evolution and characteristics of non-oncologist-prescribed sorafenib-receiving patients. (A) Percentage (black line) and absolute numbers (grey line) of patients receiving sorafenib prescriptions by GI/Hep by year. (B) Distribution of BCLC Stage of patients receiving sorafenib prescribed by oncologists or GI/Hep. No significant differences were obtained by Wilcoxon rank-sum tests. BCLC = Barcelona Clinic Liver Cancer, GI/Hep = gastroenterology/hepatologists.